

FREE BioSciTech BiWeekly Newsletter *15 June 2026 (Issue 51)*

**SELECTION
FROM THE PAST
TWO WEEKS**



***Hottest News In Biotech, BioResearch, Pharma, BioHealth
Highly Selected Research Papers & Patents
Best Recommended Events and Studentship
Algerian Sci-Tech News***



NEWS & COMMENTARIES



GSK Makes \$10.6 Billion Oncology Acquisition

GSK has announced it will acquire Nuvalent for \$10.6 billion all cash, gaining access to two late-stage targeted lung cancer therapies currently under FDA review and significantly expanding its oncology portfolio. The acquisition brings zidesamtinib and neladalkib, two potential best-in-class therapies designed to address efficacy and tolerability limitations of existing treatments for genetically defined forms of non-small cell lung cancer (NSCLC).

<https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/>



Google DeepMind, Google.org and Sanger Institute to launch new AI consortium for genomics

The Wellcome Sanger Institute and Google DeepMind, with support from Google.org, have announced a new artificial intelligence (AI) consortium for genomics.

Over five years, the consortium will focus on addressing data gaps through strategic data generation and building high-quality AI-ready genomic datasets. These datasets will power the next generation of AI models for biological discovery.

https://www.sanger.ac.uk/news_item/google-deepmind-google-org-and-sanger-institute-to-launch-new-ai-consortium-for-genomics/



5 Billion Gilead Paid Tubulis: Gilead Sciences agreed to acquire Tubulis GmbH for upwards of \$5 billion in a deal that significantly expands Gilead's oncology pipeline and establishes Munich as a dedicated antibody-drug conjugates (ADC) research hub within the company. Gilead is set to pay \$3.15 billion in upfront cash consideration, with up to \$1.85 billion in additional contingent milestone payments.¹ The transaction is expected to close in the second quarter of 2026 and will be financed through a combination of cash on hand and senior unsecured notes. it.

<https://www.pharmexec.com/view/gilead-enters-5-billion-agreement-acquire-tubulis>



SiranBio & GSK Deal. GSK have entered into a new deal with Suzhou Siran Biotechnology Co., Ltd (SiranBio) for a worldwide licensing agreement (excluding mainland China, Hong Kong, Macau and Taiwan) for SA030, a potential first-in-disease, long-acting, small interfering RNA (siRNA) oligonucleotide in development for treatment of metabolic and vascular disease. SA030 has recently entered phase I trials and targets activin receptor-like kinase 7 (ALK7), an established therapeutic mechanism for cardiometabolic disease

<https://www.siranbio.com/en/news/html/?38.html>

NEWS & COMMENTARIES



Nature Index 2026 Research Leaders: Leading institutions

The 2026 Research Leaders are based on Nature Index data from 1 January 2025 to 31 December 2025
<https://www.nature.com/nature-index/research-leaders/2026/institution/all/all/global>

Position	Institution	Share 2024	Share 2025	Count 2025	Change in Share 2024-2025
1	Chinese Academy of Sciences (CAS), China	3183.548087	3655.101321	12822	0.148
2	Zhejiang University (ZJU), China	1040.620725	1276.853852	3213	0.227
3	Harvard University, United States of America (USA)	1251.700477	1259.010206	4246	0.006
4	Tsinghua University, China	1022.430426	1213.592761	4062	0.187
5	Shanghai Jiao Tong University (SJTU), China	948.2902341	1191.473837	3301	0.256
6	University of Science and Technology of China (USTC), China	939.747209	1128.577323	3763	0.201
7	Peking University (PKU), China	913.3454836	1066.491527	4264	0.168
8	University of Chinese Academy of Sciences (UCAS), China	919.5147434	1055.667705	5191	0.148
9	Nanjing University (NJU), China	817.6194369	952.6487468	2609	0.165
10	Sichuan University (SCU), China	660.6823971	880.9271572	1721	0.333
11	Fudan University, China	717.6307136	872.5042401	2662	0.216
12	Sun Yat-sen University (SYSU), China	769.0967385	839.240069	2160	0.091
13	Max Planck Society, Germany	780.4419542	764.093117	3218	-0.021
14	Stanford University, United States of America (USA)	676.3761375	711.5306673	2348	0.052
15	Xi'an Jiaotong University (XJTU), China	568.4966762	708.4479071	1528	0.246
16	French National Centre for Scientific Research (CNRS), France	674.6456315	701.9804467	5212	0.041
17	Huazhong University of Science and Technology (HUST), China	591.213716	697.9452384	1527	0.181
18	Helmholtz Association of German Research Centres, Germany	663.3185837	681.9976963	3406	0.028
19	Jilin University (JLU), China	520.2215688	651.7114577	1332	0.253
20	Shandong University (SDU), China	470.0368371	615.7657064	1813	0.31

The Top Is CAS



中国科学院
CHINESE ACADEMY OF SCIENCES

15 out of the top 20 institutions are Chinese

PATENTS WATCH

WO2026112428 discloses a novel class of cyclic peptide modulators of the neonatal Fc receptor (FcRn) designed to regulate the pharmacokinetics of IgG antibodies and potentially treat a broad range of autoimmune and antibody-mediated diseases **Inventor: Covant Therapeutics.**

WO2026112108 discloses humanised peptide–polymer conjugates designed to achieve prolonged tissue retention, reduced dosing frequency, improved stability, and enhanced manufacturability of therapeutic peptides, particularly anti- VEGF biologics. **Inventor: Valitor.**

WO2026112287 discloses a novel class of single-domain bispecific antibodies simultaneously targeting the α - and β -subunits of the interleukin-10 receptor (IL-10R α and IL-10R β), representing an unconventional immunomodulatory strategy aimed at selectively blocking IL-10 signalling within myeloid cells while avoiding widespread activation of T cells and B cells. **Inventor: Gilead Sciences**

WO2026107318 discloses a novel CD19/CD20 bispecific B-cell depleting antibody incorporating dual Fc domains, designed to achieve extremely rapid, profound, and durable depletion of both circulating and tissue-resident B cells. **Inventor: Hinge Bio.**



WIPO



SELECTED PUBLICATIONS



Highlights from the
2026 ASCO Annual Meeting
May 30

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 30, 2026. These scientific highlights are also available online for your future review and reference.

https://www.sitcancer.org/blogs/thomas-martin/2026/05/31/2026-asco-annual-meeting-scientific-highlights-may?_zs=8KHKg&_zl=V2k15

ASCO 2026 Hottest Paper-NEWS:

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O'Reilly et al., 2026

DOI: [10.1056/NEJMoa2605555](https://doi.org/10.1056/NEJMoa2605555)



Current therapies for metastatic pancreatic ductal adenocarcinoma (mPDAC) show limited benefits. The RAS pathway is a key driver, with mutations present in more than 90% of cases. In a phase 3 trial, patients previously treated for mPDAC were assigned to receive daraxonrasib or chemotherapy. Results indicated a median overall survival of 13.2 months for daraxonrasib versus 6.6 months for chemotherapy in the RAS G12 population. Progression-free survival was 7.3 months for daraxonrasib and 3.5 months for chemotherapy.

Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells


Jaume Barcelo et al., 2026

DOI: [10.1016/j.isci.2026.116031](https://doi.org/10.1016/j.isci.2026.116031)

Rho kinase (ROCK) is vital for the survival of some cancer cells, particularly highly de-differentiated and invasive cells from solid tumors. A systematic analysis reveals that ROCK inhibition significantly reduces the survival of these cells, with a transcriptomic analysis showing increased genes associated with epithelial-to-mesenchymal transition, migration, and inflammation. Acute myeloid leukemia (AML) demonstrates a high sensitivity to ROCK inhibitors among hematological malignancies. Validation in breast cancer, melanoma, and AML confirms the reliance on Rho-ROCK-myosin II signaling for survival, raising pre-clinical considerations regarding the use of ROCK inhibitors in patient-derived organoids, which could adversely affect critical cancer cell populations.



SELECTED PUBLICATIONS



Chromatin architectures underlying plasmid-based assays for regulatory variant effects

Mallory et al., 2026

DOI: [10.1016/j.molcel.2026.04.027](https://doi.org/10.1016/j.molcel.2026.04.027)


Plasmids have revolutionized the study of regulatory grammar across life forms, yet the formation of chromatin structures on transfected plasmids in mammalian cells is not well understood. We introduced plasmid single-molecule chromatin fiber sequencing (plasmid Fiber-seq) to map chromatin architectures on full-length plasmids at near-single-nucleotide resolution. This method shows that plasmids are chromatinized in an organized, sequence-dependent fashion, revealing a heterogeneous and incomplete chromatin architecture compared to nuclear-encoded fibers. Key nucleosome and transcription factor occupancy is essential for transcriptional activity, with plasmids reflecting nuclear genome-encoded architectures with variable fidelity. \

A causal link between autoantibodies and neurological symptoms in long COVID

Keyla Santos Guedes de Sá et al., 2026

DOI: [10.1016/j.cell.2026.04.042](https://doi.org/10.1016/j.cell.2026.04.042)

Acute SARS-CoV-2 infection leads to the production of functional autoantibodies (AABs), which stay elevated in long COVID (LC). Research using various assays identified numerous AAB targets in LC patients, especially those with neurocognitive symptoms revealing increased AABs against CNS and peripheral nervous system proteins. IgG from these patients reacted with critical brain regions and was linked to neurological symptoms. Additionally, MED20-targeting IgG enhanced antibody-dependent phagocytosis. Transferring IgG from LC patients to mice induced symptoms resembling fatigue, balance issues, and pain, mirroring patient experiences. These results indicate a potential for targeting AABs therapeutically for specific LC patients.




Rational discovery of therapeutic PAK1 allosteric activators

Yu He et al., 2026

DOI: [10.1016/j.cell.2026.03.008](https://doi.org/10.1016/j.cell.2026.03.008)

Although kinase activators hold significant therapeutic promise, their development remains challenging and rarely achieved. Here, we report the discovery of direct small-molecule activators of p21-activated kinase-1 (PAK1), a key regulator of cardiac homeostasis, using a rational peptide-guided strategy. Targeting PAK1 autoinhibitory regulation, we identified a previously unrecognized autoinhibition-release site between the autoregulatory region and the kinase domain. Subsequent high-throughput screening and medicinal chemistry optimization yielded selective allosteric activators that enhance PAK1 activity with micromolar potency and isoform selectivity. Structural and mechanistic analyses indicate that these activators disrupt autoinhibitory regulation and promote local and global conformational transitions to the active state.



SELECTED PUBLICATIONS

The diffusion of large language models in published academic articles

Kyle Siler , 2026

DOI :[10.1073/pnas.260575412](https://doi.org/10.1073/pnas.260575412)

Large language models (LLMs) are significantly influencing academic research, with adoption rates rising from 12% in 2023 to an estimated 57% by 2025. An analysis of 7.3 million journal articles from 2020-2025 revealed a corpus of 228 focal words showing increased usage consistent with LLM output. The presence of LLM-influenced text varies considerably by region, institutional rank, publisher, discipline, and journal tier, indicating social stratification in adoption. Factors such as economic development and proximity to English as a primary language are key predictors of regional differences. Lower-ranked institutions and new for-profit publishers demonstrate higher adoption rates compared to elite universities, highlighting the need to understand the social dynamics as AI integration in academic writing deepens.




Lactylation of PD-L1 by a lactyltransferase HAT1 dictates its protein stability and tumor immune evasion

Man Shang et al., 2026

DOI:[10.1073/pnas.2537490123](https://doi.org/10.1073/pnas.2537490123)

Lysine lactylation influences protein function and is significant in various biological processes. This study identifies histone acetyltransferase 1 (HAT1) as a lactyltransferase for PD-L1, enhancing its stability by lactylating specific residues, which protects it from degradation and facilitates its trafficking. Inhibiting PD-L1 lactylation through HAT1 knockdown or mutations impedes tumor growth and boosts anti-PD-1 therapy. Lactylated PD-L1 is correlated with tumor advancement, highlighting HAT1's role in immune evasion and suggesting that targeting this pathway may enhance cancer immunotherapy.



Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus

Jair Andrade et al., 2026

DOI :[10.1073/pnas.2606206123](https://doi.org/10.1073/pnas.2606206123)

Immunity following dengue virus infection remains poorly understood, particularly regarding reinfections with the same serotype. A study involving 4,268 participants from Cebu, Philippines, and Kamphaeng Phet, Thailand, investigated long-term antibody dynamics, revealing steady decay of antibody titers over time, with half-lives of 7 to 8 years and slower decay rates in older individuals. The inclusion of homotypic reinfection in mathematical models was necessary to explain age-specific immunity patterns.



RECOMMENDED EVENTS & SCHOLARSHIPS



Harvard Radcliffe Fellowship 2027-2028
Paid Fellowship in the USA

\$78,000 Stipend | **\$5,000** Project Expenses

For scholars, researchers, writers, journalists, artists & scientists

Not a general student scholarship
Current degree students are not eligible

Deadlines
Sept 10, 2026 - Humanities, Social Sciences, Creative Arts, Nonfiction & Journalism
Oct 1, 2026 - Science, Engineering & Mathematics

TripDoc Verified Opportunity | Full guide: app.tripdoc.net

Harvard Radcliffe Fellowship 2027-2028 in the USA

Program Description

The Harvard Radcliffe Fellowship Program gives selected scholars, scientists, writers, journalists, public intellectuals, and artists the opportunity to spend a full academic year at Harvard University working on an ambitious individual project.

This fellowship is designed for people with a strong record of achievement or exceptional promise in their field. Fellows work in an interdisciplinary environment, engage with other fellows, and gain access to Harvard resources while developing a major project such as a book, film, research framework, artistic project, or other serious intellectual or creative work.

Selected fellows may receive:

- \$78,000 stipend
- \$5,000 project expense allowance
- Office or studio space at Harvard Radcliffe Institute
- Harvard appointment as visiting fellow
- Access to Harvard Library system
- Possible relocation support

<https://app.tripdoc.net/programs/harvard-radcliffe-fellowship-2027-2028-usa-paid-fellowship>



UKRI UK Research and Innovation

UK Research Innovation (UKRI), Expanding European Excellence (E3)

About this studentship

- Stipend set at the UKRI Minimum Doctoral Stipend rate. For 26/27 this is £21,805 per annum.
- Tuition/programme fees
- Contribution to research support fees for; lab consumables, travel, computing hardware, publications.
- The duration of the funding package is 4 years.

<https://lstmed.ac.uk/study/research-degrees/ukri-e3-funded-studentships/>

RECOMMENDED EVENTS & SCHOLARSHIPS



Taking programmed cell death from mechanisms to interventions

In partnership with Zhejiang University, Liangzhu Laboratory

October 22–24, 2026 — Hangzhou, China

Themes will include:

- Principles and mechanisms of cell death
- Cell death mechanisms in context
- Cell death in inflammation and immunity
- Cell death in disease and therapy
- Targeting cell death

<https://cell-press-symposia.com/cell-death-2026/conference-register.html>



Immunosenescence and intrinsic capacity: Rethinking aging outcomes

Participants will:

Describe key mechanisms of immune aging

Evaluate frameworks for measuring aging outcomes

Discuss emerging research linking immune function, gut biology, and healthspan

https://view6.workcast.net/register?cpak=8719910766737641&referrer=od&utm_campaign=webinars2026&et_rid=51389519&et_cid=5969814



Collaboration Opportunity between H3D & LifeArc

Collaboration Opportunity: Tackling the Challenge of AMR Together I 20th May 2026

Are you interested in advancing solutions for antimicrobial resistance (AMR)?

The Centre for Translational AMR Research (CTAR), a collaboration between H3D, Africa's first integrated drug discovery centre based at the University of Cape Town and LifeArc, is seeking new collaborations in the antimicrobial resistance (AMR) field. As part of our mission to accelerate the discovery and development of urgently needed antibiotics, we are inviting researchers, institutions and partners with promising chemical matter to engage with the H3D AMR team.

<https://h3d.uct.ac.za/articles/2026-05-19-collaboration-opportunity-between-h3d-lifearc>



ALGERIAN Sci-Tech NEWS

Official Launch of Emir Abdelkader Chair in Oxford



The launch of the "Emir Abdelkader Chair" at the University of Oxford on Friday in London, alongside the inauguration of the "Algeria Hall," were welcomed by the prominent figures attending the ceremony as undeniable achievements for Algeria, while paying special tribute to the President of the Republic, Abdelmadjid Tebboune.

<https://www.aps.dz/en/algeria/education-technology/mqcm1yrw-algeria-establishes-emir-abdelkader-chair-at-oxford-university>



ALGERIAN Sci-Tech NEWS



Algerian student teams made history at the 10th Huawei Global ICT Competition in Shenzhen, China, taking home three major Grand Prizes in the Network, Cloud, and Computing tracks.

Competing against more than 220,000 students from 100 countries, the Algerian delegation secured the highest awards in the following tracks:

- **Network Track Grand Prize:** Algerian student team.
- **Cloud Track Grand Prize:** Algerian student team.
- **Computing Track Grand Prize:** Algerian student team.

<https://www.huawei.com/en/news/2026/6/ict-competition-global>



Professor Elias Zerhouni (ex-NIH Director) Founded The Technology and Innovation Center for Virtual Education Systems (TIVES) in Algeria. The center was inaugurated in Algiers at the **Sidi Abdellah Science and Technology Pole**. Algerian Minister of Higher Education and Scientific Research, Kamel Baddari, officially inaugurated a new Center for Technology and Innovation in Virtual Education Systems on Monday. The ceremony took place at the Martyr Abdelhafid Ihaddaden Scientific and Technological Hub in Sidi Abdallah. Minister Baddari was accompanied by Elias Zerhouni, Advisor to the President of the Republic for Education, Higher Education, Vocational Training, and Culture. This opening signifies a significant step forward in enhancing Algeria's digital learning infrastructure and fostering innovation within its higher education institutions.

<https://techafrikanews.com/2026/06/11/algeria-launches-technology-and-innovation-centre-for-virtual-education-systems/>

FOLLOW US

 [company/102551429/admin/dashboard](https://www.linkedin.com/company/102551429/admin/dashboard)

Do Not Miss Your Next Free Issue
Thank You 😊



Produced by Dr. Mohamed Boudjelal , DZ-CNRST Member

 [mohamed-boudjelal-mba-ph-d-bb06232/](https://www.linkedin.com/in/mohamed-boudjelal-mba-ph-d-bb06232/)

Contact: admin@algeriansca-dz.org